title: Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient.
abstract: Here, we describe an HIV-infected patient with pretreatment resistance to raltegravir, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and protease inhibitors, and the ultimate ability to achieve viral suppression. Pretreatment integrase resistance testing is not routinely performed because transmitted integrase mutations conferring resistance to raltegravir are currently thought to be negligible. We suggest obtaining a pretreatment integrase genotype in patients with transmitted multiclass drug resistance in order to create an optimal first regimen and increase the chance for virological suppression.
authors: SAIC-Frederick, Inc., MD, USA. sarita.boyd@fda.hhs.gov
authors: Sarita D
authors: SD
authors: Boyd
authors: Frank
authors: F
authors: Maldarelli
authors: Irini
authors: I
authors: Sereti
authors: G Laissa
authors: GL
authors: Ouedraogo
authors: Catherine A
authors: CA
authors: Rehm
authors: Valerie
authors: V
authors: Boltz
authors: Diana
authors: D
authors: Shoemaker
authors: Alice K
authors: AK
authors: Pau
mesh_terms: D019380:Anti-HIV Agents / Q000494:pharmacology / Q000627:therapeutic use; D024882:Drug Resistance, Viral / Q000235:genetics; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy / Q000635:transmission* / Q000821:virology; D019428:HIV Integrase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics; D006801:Humans; D008875:Middle Aged; D009154:Mutation; D011760:Pyrrolidinones / Q000494:pharmacology* / Q000627:therapeutic use; D000068898:Raltegravir Potassium; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D019428:HIV Integrase Inhibitors; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium